Rapid reporting and review of an increased incidence of a known adverse event.
Sargent
D J
DJ
Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA. sargent.daniel@mayo.edu
Goldberg
R M
RM
Mahoney
M R
MR
Hillman
D W
DW
McKeough
T
T
Hamilton
S F
SF
Darcy
J M
JM
Anderson
V L
VL
Krook
J E
JE
O'Connell
M J
MJ
D016907:Adverse Drug Reaction Reporting Systems / Q000458:organization & administration* / Q000592:standards; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002986:Clinical Trials as Topic / Q000592:standards*; D017321:Clinical Trials, Phase I as Topic / Q000592:standards; D017322:Clinical Trials, Phase II as Topic / Q000592:standards; D017326:Clinical Trials, Phase III as Topic / Q000592:standards; D003967:Diarrhea / Q000139:chemically induced; D015507:Drugs, Investigational / Q000009:adverse effects; D006801:Humans; D015994:Incidence; D015337:Multicenter Studies as Topic / Q000592:standards*; D009316:National Institutes of Health (U.S.); D009503:Neutropenia / Q000139:chemically induced; D014481:United States; D014486:United States Food and Drug Administration; D014839:Vomiting / Q000139:chemically induced
D000970:Antineoplastic Agents; D015507:Drugs, Investigational